- PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
-
Kok PS, Beale P, O'Connell , Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M, on behalf of the PARAGON Investigators
- KMID: 2457159
- J Gynecol Oncol.
- 2019 Sep;30(5):e86.
- doi: 10.3802/jgo.2019.30.e86
OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON... -
- CITED
-
- Close
- SHARE
-
- Close
